Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nilotinib Clear all
Completed Phase 2 Interventional

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

NCT02947893
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth
Drug
Lead sponsor
Georgetown University
Other
Eligibility
50 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

NCT00129740
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic
Interventions
Nilotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

NCT00980018
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
19
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Parkinson's Disease

NCT03205488
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1), Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Jun 7, 2026, 4:47 AM EDT
Not listed Phase 1 Interventional

Nilotinib in Huntington's Disease

NCT03764215
View directory record Official record
Conditions
Huntington Disease
Interventions
Nilotinib 150 MG
Drug
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

NCT02081378
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Interventions
Asciminib (ABL001), Nilotinib, Imatinib, Dasatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jun 7, 2026, 4:47 AM EDT
Completed No phase listed Observational

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

NCT03045120
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
24
States / cities
Chicago, Illinois • Elk Grove Village, Illinois • Hoffman Estates, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jun 7, 2026, 4:47 AM EDT
Completed No phase listed Observational

Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

NCT02363868
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Clinton, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2015 · Synced Jun 7, 2026, 4:47 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

NCT02973711
View directory record Official record
Conditions
Leukemia, Chronic Myeloid
Interventions
Nilotinib, Ruxolitinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 1 Interventional Results available

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

NCT04205903
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Nilotinib, Nilotinib Hydrochloride Monohydrate, Paclitaxel, Questionnaire Administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jun 7, 2026, 4:47 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

NCT03516279
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Interventions
Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab
Drug · Other · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
291
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

NCT01744665
View directory record Official record
Conditions
CML
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jun 7, 2026, 4:47 AM EDT
Terminated Phase 4 Interventional Results available

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

NCT01131325
View directory record Official record
Conditions
CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Amarillo, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jun 7, 2026, 4:47 AM EDT
Active, not recruiting Phase 2 Interventional

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

NCT04626024
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
Interventions
Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
Other · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 7, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

NCT00644878
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

NCT00441155
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Nilotinib, Imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Jun 7, 2026, 4:47 AM EDT
Terminated Not applicable Interventional

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy

NCT01490775
View directory record Official record
Conditions
Chronic Phase CML
Interventions
no access to eMedonline, eMedonline access
Behavioral
Lead sponsor
Rex Cancer Center, Raleigh, NC
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Jun 7, 2026, 4:47 AM EDT
Terminated Phase 1 Interventional

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

NCT01751425
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
Dasatinib, Imatinib Mesylate, Nilotinib, Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

NCT01227577
View directory record Official record
Conditions
Chronic Myelogenous Leukemia in Chronic Phase
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
32
States / cities
Anaheim, California • Burbank, California • Concord, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jun 7, 2026, 4:47 AM EDT
Terminated No phase listed Observational

Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

NCT01073436
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Discontinuation of therapy
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Jun 7, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions
nilotinib
Drug
Lead sponsor
Andrew J. Wagner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Santa Monica, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jun 7, 2026, 4:47 AM EDT
Not listed Phase 2 Interventional

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

NCT02954978
View directory record Official record
Conditions
Parkinson Disease, Parkinsons Disease With Dementia
Interventions
Placebo Oral Capsule, Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jun 7, 2026, 4:47 AM EDT